Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-Gastric 01
2023-508276-11-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival in all randomized participants and Overall survival in third-line or later participants. Planned start Jan 2025; status: authorised.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-508276-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508276-11-00.